Anti-S1 MERS-COV IgY specific antibodies decreases lung inflammation and viral antigen positive cells in the human transgenic mouse model
AT Abbas, SA El-Kafrawy, SS Sohrab, AA Tabll… - Vaccines, 2020 - mdpi.com
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 and
causes severe and often fatal acute respiratory illness in humans. No approved prophylactic …
causes severe and often fatal acute respiratory illness in humans. No approved prophylactic …
[HTML][HTML] ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
NK Alharbi, E Padron-Regalado, CP Thompson… - Vaccine, 2017 - Elsevier
Abstract The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected more
than 1900 humans, since 2012. The syndrome ranges from asymptomatic and mild cases to …
than 1900 humans, since 2012. The syndrome ranges from asymptomatic and mild cases to …
Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus
J Tang, N Zhang, X Tao, G Zhao, Y Guo… - Human vaccines & …, 2015 - Taylor & Francis
Middle East respiratory syndrome (MERS) is an emerging infectious disease caused by
MERS coronavirus (MERS-CoV). The continuous increase of MERS cases has posed a …
MERS coronavirus (MERS-CoV). The continuous increase of MERS cases has posed a …
Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection
Y Wang, W Tai, J Yang, G Zhao, S Sun… - Human vaccines & …, 2017 - Taylor & Francis
Middle East respiratory syndrome (MERS) continues to raise worldwide concerns due to its
pandemic potential. Increased MERS cases and no licensed MERS vaccines highlight the …
pandemic potential. Increased MERS cases and no licensed MERS vaccines highlight the …
MERS-CoV spike protein: targets for vaccines and therapeutics
The disease outbreak caused by Middle East respiratory syndrome coronavirus (MERS-
CoV) is still ongoing in the Middle East. Over 1700 people have been infected since it was …
CoV) is still ongoing in the Middle East. Over 1700 people have been infected since it was …
Receptor-binding domain-based subunit vaccines against MERS-CoV
N Zhang, J Tang, L Lu, S Jiang, L Du - Virus research, 2015 - Elsevier
Abstract Development of effective vaccines, in particular, subunit-based vaccines, against
emerging Middle East respiratory syndrome (MERS) caused by the MERS coronavirus …
emerging Middle East respiratory syndrome (MERS) caused by the MERS coronavirus …
[HTML][HTML] Advances in mRNA and other vaccines against MERS-CoV
Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic human
coronavirus (CoV). Belonging to the same beta-CoV genus as severe acute respiratory …
coronavirus (CoV). Belonging to the same beta-CoV genus as severe acute respiratory …
Characterization of the immune response of MERS-CoV vaccine candidates derived from two different vectors in mice
E Li, F Yan, P Huang, H Chi, S Xu, G Li, C Liu, N Feng… - Viruses, 2020 - mdpi.com
Middle East respiratory syndrome (MERS) is an acute, high-mortality-rate, severe infectious
disease caused by an emerging MERS coronavirus (MERS-CoV) that causes severe …
disease caused by an emerging MERS coronavirus (MERS-CoV) that causes severe …
MERS-CoV spike nanoparticles protect mice from MERS-CoV infection
CM Coleman, T Venkataraman, YV Liu, GM Glenn… - Vaccine, 2017 - Elsevier
Abstract The Middle East respiratory syndrome coronavirus (MERS-CoV) was first
discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths …
discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths …
[HTML][HTML] Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein
J Goo, Y Jeong, YS Park, E Yang, DI Jung, S Rho… - Virus research, 2020 - Elsevier
Abstract Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes severe
pulmonary infection, with∼ 35% mortality. Spike glycoprotein (S) of MERS-CoV is a key …
pulmonary infection, with∼ 35% mortality. Spike glycoprotein (S) of MERS-CoV is a key …